HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintained a $10 price target.
June 26, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reviva Pharmaceuticals (NASDAQ:RVPH) received a reiterated Buy rating from HC Wainwright & Co. analyst Raghuram Selvaraju, with a maintained $10 price target.
The reiterated Buy rating from HC Wainwright & Co. analyst Raghuram Selvaraju is a positive signal for Reviva Pharmaceuticals. The maintained $10 price target indicates that the analyst believes the stock has potential for growth in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100